Avalo Therapeutics (Avalo Therapeutics) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Debt-to-Equity?

Avalo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.54 Mil. Avalo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Avalo Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7.30 Mil. Avalo Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avalo Therapeutics's Debt-to-Equity or its related term are showing as below:

AVTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.83 Med: 0.05 Max: 11.37
Current: 0.07

During the past 11 years, the highest Debt-to-Equity Ratio of Avalo Therapeutics was 11.37. The lowest was -1.83. And the median was 0.05.

AVTX's Debt-to-Equity is ranked better than
66.29% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs AVTX: 0.07

Avalo Therapeutics Debt-to-Equity Historical Data

The historical data trend for Avalo Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Debt-to-Equity Chart

Avalo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

1.44

-1.83

0.07

Avalo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.83	-3.24	-2.10	0.04	0.07

Competitive Comparison of Avalo Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Avalo Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Debt-to-Equity falls into.

Avalo Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avalo Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.537	+	0)	/	7.304
	=	0.07

Avalo Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.537	+	0)	/	7.304
	=	0.07

Avalo Therapeutics (NAS:AVTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Avalo Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

C6K0:Germany C6K0:Germany

Address

540 Gaither Road, Suite 400, Rockville, MD, USA, 20850

Website

https://www.avalotx.com

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Executives

Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd.	10 percent owner	PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan	officer: Interim CFO	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil	officer: Chief Medical Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski	officer: Chief Commercial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson	director	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller	director	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway	officer: CFO & Treasurer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins	officer: Chief Medical Officer	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr	officer: Chief Commercial Officer	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022